PQQ OCT Glutathione Vitamin K2 Coenzyme Q10 Vegan Vitamin D3 Creatine monohydrate L-methylfolate DTF powder and Film Microencapsulated Vitamins
Dyestuff Nutrition Pharmaceutical DTF Powder and DTF Film
Nutrition news Dyestuff news Vitamins Knowledge L-Methylfolate Knowledge
Release time：2026-05-02 Click:
Home >News >Nutrition news
The dietary supplement and functional food industry is currently witnessing a massive influx of capital and research directed toward mitochondrial health and cellular longevity. At the forefront of this movement is Urolithin A, a highly researched postbiotic metabolite naturally produced by the human gut microbiome from dietary ellagitannins found in pomegranates, berries, and nuts. However, for B2B ingredient buyers, contract manufacturers, and supplement brand owners, clinical efficacy is only secondary to regulatory compliance. Navigating the United States Food and Drug Administration (FDA) safety consensus on new dietary ingredients is the critical first step in commercialization. Formulating with non‑compliant ingredients exposes brands to regulatory recalls, supply chain disruptions, and severe legal liabilities.
Before a novel compound can be introduced into the United States market as a dietary supplement or food additive, it must satisfy specific safety criteria established by the FDA under the Federal Food, Drug, and Cosmetic (FD&C) Act. For ingredients that were not marketed in the US prior to October 15, 1994, manufacturers typically have two primary regulatory pathways: submitting a New Dietary Ingredient (NDI) notification or establishing that the ingredient is Generally Recognized As Safe (GRAS).
The GRAS framework is particularly vital for B2B ingredient suppliers. For a substance to achieve GRAS status, there must be a consensus among qualified experts that the ingredient is safe under the conditions of its intended use. This consensus must be based on publicly available scientific data, including rigorous toxicological studies, and the safety profile must be equivalent to that required for an approved food additive. Manufacturers can choose to convene an independent expert panel to achieve ”Self‑Affirmed GRAS“ status, but the gold standard for market acceptance—and the benchmark expected by top‑tier supplement brands—is submitting a GRAS notice to the FDA and receiving a ”No Questions“ letter. Receiving such a letter signals that the FDA has reviewed the manufacturer’s safety dossier and does not dispute the expert panel‘s conclusion. Notably, Urolithin A Wholesale buyers should always verify that their source holds this critical FDA recognition, as the No Questions letter is specific to each manufacturing process and purity specification, not a blanket endorsement of all Urolithin A on the market.
The regulatory landscape is also evolving. In 2026, the FDA announced significant GRAS reforms under its Human Foods Program priorities, including a proposed rule that would require mandatory submission of GRAS notices for all substances claimed to be GRAS, a potential shift from the current self‑affirmed pathway. These changes underscore the growing importance of having a formal, FDA‑reviewed GRAS dossier for any ingredient destined for the US market.
Because Urolithin A is produced in the human gut in trace amounts and is not consumed directly in high concentrations through a standard diet, commercially viable Urolithin A is synthesized or extracted. The FDA views this highly concentrated, manufactured form as a novel ingredient, necessitating an exhaustive toxicological profile to prove its safety for human consumption. Whether you are evaluating Bulk Urolithin A Powder from a prospective partner or considering a transition to Water‑soluble Urolithin A for enhanced bioavailability in liquid formulations, the toxicological data package must be equally robust.
The regulatory pathway for Urolithin A was pioneered by Amazentis SA, which submitted a GRAS notice for its proprietary synthesized Urolithin A, branded as Mitopure. The FDA filed this notice as GRN 791 and subsequently issued a ”No Questions“ letter, allowing its use in specific food categories and dietary supplements. Analyzing the data within GRN 791 provides a clear blueprint of the FDA’s expectations regarding Urolithin A safety.
To establish safety, the notification relied on extensive in vitro and in vivo studies. The genotoxicity profile was evaluated using a bacterial reverse mutation assay (the Ames test) and an in vitro mammalian cell micronucleus assay, both of which returned negative results, indicating that Urolithin A does not induce genetic mutations or chromosomal damage.
When evaluating the systemic toxicity data, a narrative comparison of the dosage parameters reveals an exceptionally wide safety margin. In a 90‑day subchronic oral toxicity study conducted on rats, the researchers established a No‑Observed‑Adverse‑Effect Level (NOAEL). For male rats, the NOAEL was determined to be 3,451 milligrams per kilogram of body weight per day. For female rats, the NOAEL was slightly higher, recorded at 3,826 milligrams per kilogram of body weight per day.
We must compare these toxicological endpoints to the intended human exposure to understand the FDA‘s safety consensus. The maximum intended dietary intake for Urolithin A proposed in the GRAS notification is 1,000 milligrams per person per day. For a standard adult weighing 70 kilograms, this equates to an exposure of approximately 14.2 milligrams per kilogram of body weight per day. By comparing the male rat NOAEL of 3,451 milligrams to the human equivalent exposure of 14.2 milligrams, we can observe a safety margin that exceeds a factor of 240. The FDA traditionally requires a minimum safety margin of 100‑fold for food additives; thus, the data provided for Urolithin A far surpasses the baseline regulatory threshold for safety. Human clinical trials have since confirmed this safety profile, demonstrating that Urolithin A is well‑tolerated in daily doses up to 1,000 mg for extended periods, with no serious adverse events reported and normal organ function maintained across liver, kidney, and cardiac markers.
For dietary supplement formulators and food scientists, the parameters established within the GRAS notifications dictate exactly how Urolithin A can be utilized in consumer products. The FDA safety consensus is not a blanket approval for unlimited use; it is strictly tied to specific food categories and inclusion rates.
According to the GRAS precedent, Urolithin A is permitted for use in a variety of functional food matrices beyond traditional capsules and tablets. These include protein shakes, meal replacement drinks, nutrition bars, and yogurt products. However, the inclusion rate must be carefully calculated. For example, a formulator developing a functional nutrition bar must ensure that the Urolithin A content does not exceed 500 milligrams per serving, whereas a powdered meal replacement might be formulated to deliver up to 1,000 milligrams per serving, provided the total daily intake instructions do not exceed the established maximums. For brands interested in Water‑soluble Urolithin A, these dosing guidelines remain fully applicable, irrespective of the delivery format, as the safety determination is based on total daily intake, not the physical form of the ingredient.
The regulatory status of Urolithin A in the United States is firmly anchored by the FDA GRAS notification process. The comprehensive toxicological data, demonstrating a safety margin exceeding 240‑fold compared to intended human use, provides a secure foundation for product development. For Brand owner and manufacturers, prioritizing Urolithin A sources that strictly adhere to these established purity, contaminant, and dosage specifications is not merely a legal obligation, but a strategic imperative for ensuring supply chain integrity and long‑term commercial success in the longevity supplement sector. Partnering with a credible Urolithin A Raw Material Supplier who can provide full regulatory documentation—from synthesis methods to impurity profiles—is the most effective way to protect your brand and accelerate product innovation.
As a trusted Urolithin A Raw Material Supplier with rigorous quality standards and full regulatory documentation, LeadingChem empowers your brand success from lab to market. Contact Us Today to request samples and discover how our premium ingredients can elevate your next formulation.
[1] U.S. Food and Drug Administration. (2018). GRAS Notice (GRN) No. 791: Urolithin A.
[2] European Food Safety Authority (EFSA). (2021). Safety of Urolithin A as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal.
[3] Heilman, J., et al. (2017). Safety assessment of Urolithin A, a metabolite produced by the human gut microflora upon dietary intake of plant derived ellagitannins. Food and Chemical Toxicology.
[4] U.S. Food and Drug Administration. (2026). Human Foods Program 2026 Priority Deliverables.
[5] U.S. Food and Drug Administration. (2025). FDA GRAS Notice Inventory – Annual Summary 2025.
